Affinage

MAX

Protein max · UniProt P61244

Length
160 aa
Mass
18.3 kDa
Annotated
2026-06-10
100 papers in source corpus 33 papers cited in narrative 34 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

MAX is a constitutively expressed nuclear bHLH-leucine zipper phosphoprotein that serves as the obligate dimerization hub of the MYC transcriptional network, with virtually all newly synthesized Myc found complexed with the stable, constant Max partner in cells (PMID:1730411, PMID:1501888). Max requires intact HLH and leucine zipper motifs to interact with c-Myc and carries a C-terminal nuclear localization signal, but lacks an intrinsic activation domain, functioning instead as a cofactor that on its own represses CACGTG (E-box) reporters until Myc co-expression relieves repression (PMID:1730412, PMID:1406956). Max homodimers and Myc-Max heterodimers both bind E-box DNA as dimers, while full-length c-Myc cannot bind DNA without Max (PMID:1730412, PMID:1501888); crystal structures of Myc-Max and Mad-Max heterodimers show quasisymmetric architectures resembling the Max homodimer, with coiled-coil leucine-zipper differences dictating partner preference and a Myc-Max-specific bivalent heterotetramer linking distant E-boxes (PMID:12553908). Max additionally heterodimerizes with the repressive partners Mad, Mxi1, Mnt, and (via the Max-like protein Mlx) Mad1/Mad4, which silence the same E-box targets by recruiting the mSin3A-HDAC corepressor complex, so the balance among competing Max complexes governs proliferation, differentiation, and apoptosis (PMID:8425218, PMID:8425219, PMID:9308234, PMID:10593926); differentiation drives a switch from Myc:Max to Mad:Max complexes, and Mnt:Max-to-Myc:Max switching controls cell-cycle entry (PMID:8224841, PMID:15866886). Max activity is tuned post-translationally by CKII phosphorylation of N-terminal serines Ser-2/Ser-11, which alters DNA-binding kinetics, by p300-mediated acetylation of lysines required for nuclear localization and Myc suppression, by an intramolecular interaction between the disordered N-terminus and the DNA-binding domain that accelerates binding and confers E-box specificity, and by alternative-splicing isoforms with opposing growth-regulatory properties (PMID:1737614, PMID:8247525, PMID:17217336, PMID:36174765, PMID:1566084, PMID:9211884). Max acts as a direct epigenetic sensor through Arg36-mediated recognition of 5-carboxylcytosine in the E-box CpG (PMID:27903915). Germline loss-of-function mutations in MAX cause hereditary pheochromocytoma, and MAX inactivation is an early event in gastrointestinal stromal tumors, establishing MAX as a tumor suppressor that constrains MYC protein stability and oncogenic transcription (PMID:21685915, PMID:28270683, PMID:31395740).

Mechanistic history

Synthesis pass · year-by-year structured walk · 19 steps
  1. 1992 High

    Established that Myc, an oncoprotein unable to bind DNA alone, acts only through an obligate partner — identifying Max as that constitutive nuclear partner and defining the heterodimeric DNA-binding unit.

    Evidence Reciprocal co-IP, DNA-binding assays, metabolic labeling and fractionation; cross-linking EMSA with bacterial proteins

    PMID:1323849 PMID:1501888 PMID:1730411 PMID:1730412

    Open questions at the time
    • Did not define the full repertoire of Max partners beyond Myc
    • Did not establish in vivo transcriptional consequences genome-wide
  2. 1992 High

    Mapped Max functional architecture and showed Max alone represses E-box reporters relieved by Myc, establishing Max as a partner-dependent regulatory switch rather than an independent activator.

    Evidence Deletion/domain mapping, NLS localization, transient reporter assays with domain mutants

    PMID:1406956 PMID:1730412

    Open questions at the time
    • Mechanism of repression by Max homodimers not defined at this stage
    • No corepressor identified yet
  3. 1992 High

    Defined post-translational and isoform-level control of Max DNA binding, showing CKII phosphorylation differentially regulates Max homodimers versus Myc:Max heterodimers and that splice variants have opposing transforming effects.

    Evidence In vitro CKII kinase assays with mutagenesis and phosphatase treatment; cDNA cloning and Myc-Ras cotransformation

    PMID:1566084 PMID:1737614

    Open questions at the time
    • Physiological signal controlling CKII activity on Max not identified
    • delta-Max evidence is single-lab functional assay
  4. 1993 High

    Discovered the repressive arm of the network — Mad and Mxi1 form Max heterodimers at the same E-box sites — establishing competition among activating and repressing Max complexes as the regulatory logic.

    Evidence Library screen with radiolabeled Max, yeast interaction trap, EMSA, transactivation assays; in vivo co-IP during myeloid differentiation

    PMID:8224841 PMID:8425218 PMID:8425219

    Open questions at the time
    • Corepressor machinery not yet identified in these reports
    • Direct target genes of repression not enumerated
  5. 1993 Medium

    Refined DNA recognition rules and kinetic tuning, showing flanking-sequence preferences distinguish Myc:Max from Max:Max binding and that CKII phosphorylation at Ser-2/Ser-11 governs binding on/off rates.

    Evidence Site-selection, EMSA, transactivation assays; in vitro phosphorylation with binding kinetics; identification of a direct target (ODC promoter)

    PMID:8247525 PMID:8262968 PMID:8265351 PMID:8430110

    Open questions at the time
    • Genome-wide validation of flanking-sequence rules lacking
    • ODC target shown in single-lab reporter context
  6. 1994 Medium

    Showed Max homodimers, unlike truncated Myc homodimers, can engage nucleosomal E-boxes, implicating partner choice in chromatin access.

    Evidence In vitro nucleosome binding with reconstituted chromatin templates

    PMID:8196648

    Open questions at the time
    • Not tested with full-length Myc:Max in vivo
    • Chromatin remodeling requirements not addressed
  7. 1996 Medium

    Demonstrated evolutionary conservation of the Myc/Max heterodimer and its E-box function in Drosophila, supporting a conserved transcriptional mechanism.

    Evidence cDNA cloning, heterodimerization, DNA binding, transcription assays, genetic mapping

    PMID:8929412

    Open questions at the time
    • Did not address Max-independent Myc functions later revealed
  8. 1997 Medium

    Linked Max isoform identity and additional repressors (Mnt) to growth and apoptotic outcomes, and defined the SID-mSin3 repression module of the network.

    Evidence Stable overexpression growth/apoptosis assays, in vitro DNA binding, reporter assays; co-IP and SID deletion mutagenesis for Mnt

    PMID:9211884 PMID:9308234

    Open questions at the time
    • Single-lab functional studies
    • Endogenous balance of isoforms in vivo not quantified
  9. 1999 Medium

    Defined the Mad-Mlx repression branch requiring mSin3A-HDAC recruitment and connected Max induction to cell-survival signaling, broadening the network's physiological reach.

    Evidence Interaction screening, co-IP, EMSA, reporter assays, mSin3A co-IP; qPCR, plasmid/antisense manipulation and apoptosis rescue in endothelial cells

    PMID:10446908 PMID:10593926

    Open questions at the time
    • Single-lab studies
    • Mechanism linking adrenomedullin signaling to Max transcription not resolved
  10. 2003 High

    Provided the structural basis for partner discrimination and Myc-specific gene activation, showing leucine-zipper differences dictate dimer preference and a Myc-Max heterotetramer bridges distant E-boxes.

    Evidence X-ray crystallography of Myc-Max and Mad-Max bHLHZ:E-box complexes at 1.9–2.0 Å

    PMID:12553908

    Open questions at the time
    • Full-length disordered regions not in the crystallized constructs
    • Tetramer functional role inferred, not directly tested in vivo here
  11. 2004 Medium

    Quantified the comparable E-box affinities of Max:Max and Myc:Max and identified small-molecule competition with Max-DNA binding.

    Evidence Surface plasmon resonance, fluorescence binding, EMSA; curcuminoid inhibitor characterization

    PMID:14980448

    Open questions at the time
    • Truncated constructs used
    • Inhibitor specificity/cellular efficacy not established
  12. 2005 High

    Connected network complex switching to cell-cycle entry and defined the biophysical consequences of the full-length disordered Max termini on dimerization.

    Evidence Co-IP, ChIP, Cre-lox Mnt/c-Myc double-knockout epistasis in MEFs; CD/NMR/AUC on full-length p21 Max

    PMID:15866886 PMID:16171389

    Open questions at the time
    • Mechanistic basis of electrostatic weakening of full-length dimer biology in vivo not tested
    • Switching kinetics on individual targets not resolved
  13. 2007 High

    Established acetylation as a regulatory layer controlling Max nuclear localization and its suppression of Myc, identifying p300 as the modifying enzyme.

    Evidence MS site mapping, in vitro p300 acetylation, cellular HDAC-inhibitor/p300 assays, reporter and localization readouts

    PMID:17217336

    Open questions at the time
    • Deacetylase for Max not identified
    • Dynamics of acetylation across cell states not addressed
  14. 2008 High

    Revealed that key Myc activities can proceed without Max, redefining Max as essential for some but not all Myc functions.

    Evidence Drosophila Max loss-of-function genetics, Myc dimerization-mutant analysis, RNA Pol III transcription assay

    PMID:19165923

    Open questions at the time
    • Extent of Max-independent Myc activity in mammals not quantified here
    • Alternative Myc partners for these activities not identified
  15. 2011 High

    Established MAX as a tumor suppressor by identifying causative germline loss-of-function mutations in hereditary pheochromocytoma with confirmed protein loss and LOH.

    Evidence Exome and validation sequencing, MAX IHC, LOH/uniparental disomy analysis

    PMID:21685915

    Open questions at the time
    • Mechanism linking MAX loss to pheochromocytoma transformation not fully defined here
    • Tissue-specificity of the tumor suppressor effect unexplained
  16. 2014 Medium

    Identified hypoxia-induced unproductive splicing as a mechanism to downregulate MAX protein, linking environmental stress to network output.

    Evidence RT-PCR isoform detection, protein stability and NMD-inhibition assays, heterologous stability reporter

    PMID:25451222

    Open questions at the time
    • Single-lab study
    • Transcriptional consequences of hypoxic MAX loss not mapped genome-wide
  17. 2017 High

    Defined MAX as a direct epigenetic sensor of cytosine carboxylation and characterized its DNA-binding arginines as cancer mutation hotspots, and showed MAX loss is an early, reversible driver in GIST.

    Evidence Quantitative binding, X-ray crystallography of MAX–5caC E-box, mutagenesis, myeloma genome analysis; NGS, IHC and MAX re-expression rescue with p16/proliferation readouts in GIST

    PMID:27903915 PMID:28270683

    Open questions at the time
    • In vivo prevalence and dynamics of 5caC at MAX-bound E-boxes not established
    • Mechanism by which MAX loss silences p16 not fully defined
  18. 2019 High

    Demonstrated that MAX is required for MYC-driven lymphomagenesis and that MAX loss destabilizes MYC protein, mechanistically linking the dimerization hub to MYC oncoprotein stability.

    Evidence B-cell-specific Cre-lox Max deletion in Eµ-Myc mice, RNA-seq, ChIP-seq, western blot; dimerization-inhibitor treatment of cell lines

    PMID:31395740

    Open questions at the time
    • Identity of the MYC-stability regulators downstream of MAX not fully resolved
    • Whether MYC destabilization fully accounts for tumor suppression unclear
  19. 2022 High

    Resolved how the disordered MAX N-terminus regulates the folded DNA-binding domain, showing an intramolecular, DNA-competitive electrostatic interaction that accelerates binding and confers E-box specificity, enhanced by CKII phosphorylation.

    Evidence NMR interaction mapping, SPR DNA-binding kinetics, in vitro CKII phosphorylation

    PMID:36174765

    Open questions at the time
    • In vivo relevance of the intramolecular regulation not tested
    • Interplay with acetylation not examined

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the competing Max complexes are quantitatively partitioned at endogenous loci in real time, and how this partitioning integrates phosphorylation, acetylation, splicing, and 5caC sensing to set proliferative versus tumor-suppressive output, remains unresolved.
  • No integrated quantitative model of complex competition at single loci
  • Signal-to-PTM linkages for Max regulation incomplete
  • Deacetylase and full degradation machinery for Max not identified

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003677 DNA binding 4 GO:0140110 transcription regulator activity 4 GO:0060090 molecular adaptor activity 3 GO:0140299 molecular sensor activity 1
Localization
GO:0005634 nucleus 3 GO:0005654 nucleoplasm 2
Pathway
R-HSA-1643685 Disease 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-4839726 Chromatin organization 3 R-HSA-1640170 Cell Cycle 2
Complex memberships
MAX homodimerMad-MAX heterodimerMnt-MAX heterodimerMyc-MAX heterodimer

Evidence

Reading pass · 34 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1992 Myc and Max associate in vivo: coimmunoprecipitation with anti-Myc and anti-Max antibodies showed that essentially all newly synthesized Myc is complexed with Max in cells; the complex possesses specific DNA-binding activity for CACGTG-containing oligonucleotides; Max is a stable nuclear phosphoprotein whose expression level is constant across quiescent, mitogen-stimulated, and cycling cells, whereas Myc is rapidly degraded during/after association with Max. Coimmunoprecipitation, DNA binding assay, metabolic labeling, subcellular fractionation Genes & development High 1730411
1992 Max functional domains mapped: Max requires intact HLH and leucine zipper motifs for intracellular interaction with c-Myc; a nuclear localization signal (PQSRKKLR) was mapped to the carboxy-terminal region of Max; Max lacks a transcriptional activation domain functional in CHO cells, suggesting it acts as a cofactor or transcriptional repressor. Fusion protein expression in cultured cells, deletion analysis, coimmunoprecipitation, reporter gene assay Genes & development High 1730412
1992 Max overexpression represses transcription of a CACGTG-containing reporter gene in mammalian cells, and this repression is relieved by co-expression of c-Myc; repression requires the Max DNA-binding domain, while relief requires Myc dimerization and transactivation domains. Transient transfection reporter gene assay in mammalian cells, domain deletion analysis Nature High 1406956
1992 Max homodimers and c-Myc/Max heterodimers both bind CACGTG-containing DNA sequences using a dimeric structure (demonstrated by chemical and photo-cross-linking); full-length c-Myc alone cannot bind DNA but does so in complex with Max. Chemical and photo-cross-linking, electrophoretic mobility shift assay (EMSA), bacterially produced proteins Genes & development High 1730412
1992 Casein kinase II (CKII) phosphorylates Max homodimers in vitro and inhibits their DNA-binding activity in an ATP-dependent manner; this inhibition maps to a CKII phosphorylation site in the amino terminus of Max; Myc/Max heterodimer DNA-binding activity is not inhibited by CKII phosphorylation; Max is phosphorylated in NIH-3T3 cells and can bind DNA after phosphatase treatment or heterodimerization with Myc. In vitro kinase assay with purified bovine CKII, EMSA, deletion analysis and site-directed mutagenesis, phosphatase treatment, immunoprecipitation from cells Genes & development High 1737614
1992 An alternatively spliced mRNA encodes delta-Max, a truncated form lacking the C-terminal nuclear localization signal and putative regulatory domain; delta-Max retains binding to CACGTG in complex with c-Myc but lacks nuclear localization; in a Myc-Ras cotransformation assay, full-length Max suppresses transformation whereas delta-Max enhances it, indicating the two isoforms have opposing regulatory effects on c-Myc function. cDNA cloning, Myc-Ras cotransformation assay in rat embryo fibroblasts Science Medium 1566084
1992 c-Myc and Max homodimers bend DNA in opposite orientations when bound to CACGTG, as measured by circular permutation and phasing analysis; c-Myc-Max heterodimers cause a smaller bend in an orientation similar to Max homodimers; no specific DNA unwinding was detected. Circular permutation assay, phasing analysis, EMSA Proceedings of the National Academy of Sciences Medium 1323849
1992 In cell extracts virtually all c-Myc is associated with Max in heterodimeric complexes; c-Myc cannot bind CACGTG in the absence of Max, whereas both Max alone and c-Myc/Max bind the same DNA sequence. Cell extract EMSA, immunoprecipitation Oncogene High 1501888
1993 Mad (a bHLH-Zip protein) binds Max in vitro to form a sequence-specific DNA binding complex with properties similar to Myc-Max; Mad does not homodimerize efficiently and does not associate with Myc; Mad-Max and Myc-Max heterocomplexes are both favored over Max homodimers; CKII phosphorylation does not affect heterodimer DNA binding; in vivo transactivation assays show Myc-Max and Mad-Max have opposing transcriptional activities, with Mad-Max functioning as a repressor. Lambda gt11 library screen with radiolabeled Max protein, in vitro binding, EMSA, CKII phosphorylation assay, transactivation assay Cell High 8425218
1993 Mxi1 (Mad family bHLH-Zip protein) specifically interacts with Max to form heterodimers that bind Myc-Max consensus recognition sites (CACGTG); Mxi1-Max heterodimers do not stimulate transcription; proposed mechanism of indirect Myc inhibition by sequestering Max and competing at target sites. Yeast interaction trap, DNA binding assay Cell High 8425219
1993 Mad:Max heterocomplexes accumulate in vivo in human myeloid cells undergoing macrophage differentiation (TPA-treated U937): undifferentiated cells show only Myc:Max complexes, but within 2 hours of TPA treatment Mad:Max complexes appear, and by 48 hours only Mad:Max complexes are detectable; Mad is a nuclear phosphoprotein with a very short half-life (~15–30 min). Coimmunoprecipitation from cell lysates, pulse-chase metabolic labeling, subcellular fractionation Genes & development High 8224841
1993 c-Myc/Max and Max/Max dimers have distinct DNA-binding preferences at flanking nucleotides: the c-Myc/Max dimer fails to bind the core CACGTG when flanked by 5'T or 3'A, while Max/Max homodimers bind such sequences readily; inappropriate flanking sequences preclude Myc transactivation in vivo. Site-selection protocol, EMSA, transactivation assay Nucleic acids research Medium 8265351
1993 Two major in vivo CKII phosphorylation sites in Max identified as Ser-2 and Ser-11; phosphorylation of these sites increases both the on- and off-rates of Max homodimer and Myc/Max heterodimer DNA binding; the shorter Max isoform (p21) dissociates from DNA faster than p22; these kinetic differences could allow different Max complexes to exchange on DNA in response to changing growth conditions. In vitro kinase assay, site-directed mutagenesis, DNA binding kinetics measurements Oncogene High 8247525
1993 The c-Myc/Max protein complex directly binds the CACGTG element in the human ornithine decarboxylase (ODC) promoter, as shown by EMSA with anti-Myc/anti-Max antibodies and purified recombinant proteins; co-transfection of c-Myc and/or Max enhances ODC promoter-driven reporter expression; antisense c-Myc oligomers reduce endogenous ODC mRNA. EMSA with antibody supershift, methylation interference, transient transfection, antisense oligonucleotide treatment The Journal of biological chemistry Medium 8262968
1993 Max and c-myc proteins show distinct patterns of DNA binding across related CACGTG-containing oligonucleotides; the nine-amino-acid N-terminal insertion distinguishing Max(long) from Max(short) serves a regulatory function affecting DNA sequence recognition; phosphorylation of Max(long) in reticulocyte lysates strongly affects its DNA binding, whereas Max(short) is unaffected. Recombinant protein EMSA, phosphorylation in reticulocyte lysate Proceedings of the National Academy of Sciences Medium 8430110
1994 Max homodimers can bind CACGTG sequences in nucleosomal DNA, whereas truncated c-Myc homodimers cannot; modifying the c-Myc dimerization interface or changing its partner to Max enables nucleosomal DNA binding; domains beyond the basic region influence nucleosome binding. In vitro nucleosome binding assay with reconstituted chromatin templates Molecular and cellular biology Medium 8196648
1996 Drosophila homologs dMyc and dMax heterodimerize, recognize the same CACGTG DNA sequence as vertebrate Myc/Max, and activate transcription; dMyc is likely encoded by the diminutive (dm) locus whose loss causes small body size and female sterility. cDNA cloning, heterodimerization assay, DNA binding assay, transcription activation assay, genetic mapping Science Medium 8929412
1997 Max(L) isoform is much more effective than Max(S) at homodimeric DNA binding and can repress a c-Myc-responsive reporter gene; Max(L)-overexpressing NIH3T3 cells grow more slowly, have higher growth factor requirements, and show accelerated apoptosis after growth factor deprivation compared to Max(S)-overexpressing or control cells. In vitro DNA binding assay, stable cell line overexpression, reporter gene assay, growth assay, apoptosis assay The Journal of biological chemistry Medium 9211884
1997 Mnt is a novel Max-binding protein that interacts with Max in vivo; Mnt:Max complexes repress transcription from CACGTG-containing promoters and suppress Myc-dependent activation; transcriptional repression maps to a 13-amino-acid N-terminal SID that mediates interaction with mSin3 corepressor; deletion of the SID converts Mnt from a repressor/Myc-suppressor to an activator/cooperating oncogene. Coimmunoprecipitation, reporter gene assay, deletion mutagenesis, Myc-Ras cotransformation assay Current topics in microbiology and immunology Medium 9308234
1997 Max alpha-helical content increases upon dimerization and upon binding to CACGTG-containing double-stranded DNA; Max exists as a monomer at low protein concentration and as a dimer at high protein concentration; both dimerization and DNA binding favor increased alpha-helical structure. Circular dichroism spectroscopy, sedimentation equilibrium Journal of biochemistry Medium 9399572
1999 Mlx, a novel Max-like bHLHZip protein, forms heterodimers with Mad1 and Mad4 (but not with Myc or other Mad family members) and binds CACGTG; Mad1:Mlx heterodimer repression requires dimerization, DNA binding, and recruitment of the mSin3A-HDAC corepressor complex. Protein interaction screening, coimmunoprecipitation, EMSA, reporter gene assay, mSin3A co-IP The Journal of biological chemistry Medium 10593926
1999 Adrenomedullin and CGRP induce Max expression in quiescent rat endothelial cells, which rescues serum deprivation-induced apoptosis; antisense knockdown of Max blocks both adrenomedullin-induced Max upregulation and its cell survival effect; Max overexpression alone rescues apoptosis; adrenomedullin-induced Max negatively regulates E-box-driven transcription (e.g., preproendothelin-1 promoter). Real-time quantitative PCR, transfection of Max-expressing plasmid, antisense oligodeoxynucleotide knockdown, reporter gene assay Molecular endocrinology Medium 10446908
2003 X-ray crystal structures of Myc-Max and Mad-Max bHLHZ heterodimers bound to the CACGTG E-box determined at 1.9 Å and 2.0 Å resolution; both heterodimers are quasisymmetric and resemble the Max homodimer; structural differences in coiled-coil leucine zipper regions explain preferential homo- and heteromeric dimerization; the Myc-Max heterodimer (but not Mad-Max) dimerizes into a bivalent heterotetramer, explaining how Myc upregulates genes with widely separated E-boxes. X-ray crystallography Cell High 12553908
2004 Binding constants of Max/Max and Myc/Max dimers to E-box DNA are similar (K~7×10^6 M^-1); Max/Max dimer formation is kinetically easier than Myc/Max dimer formation for truncated b/HLH/Zip proteins, but domains outside b/HLH/Zip are important for physiological transcriptional regulation; curcuminoid 004 inhibits Max/Max-DNA binding with a dissociation constant of ~9 μM by competing with DNA. Surface plasmon resonance kinetics, fluorescence-based binding assay, EMSA with cell extract Biochimica et biophysica acta Medium 14980448
2005 Mnt-Max to c-Myc-Max complex switching regulates cell cycle entry: c-Myc induction during G0-to-S transition causes a transient decrease in Mnt-Max complexes and a switch in the ratio of Mnt-Max to c-Myc-Max on shared target genes; Mnt overexpression suppresses cell cycle entry; Cre-lox deletion of both Mnt and c-Myc rescues the cell cycle block caused by c-Myc ablation alone. Coimmunoprecipitation, chromatin immunoprecipitation (ChIP), cell cycle analysis, Cre-lox genetic epistasis in MEFs The Journal of cell biology High 15866886
2005 The complete p21 Max gene product has unstructured N- and C-terminal regions flanking the folded bHLH-LZ; p21 Max homodimerizes with an apparent KD ~7×10^-6 M at 37°C (10–100× weaker than the isolated bHLH-LZ alone, due to electrostatic repulsions); a double-mutant p21 Max forms a highly stable dimer (KD ~3×10^-10 M) with a higher DNA-complex melting temperature. Circular dichroism, NMR, analytical ultracentrifugation (sedimentation equilibrium), fluorescence-based dimerization assay Biochemistry Medium 16171389
2007 Max is acetylated in vivo at Lys-57, Lys-144, and Lys-145; acetylation is stimulated by HDAC inhibitors and by p300 overexpression; the p300 HAT directly acetylates Max in vitro at these three residues; the three acetylated lysines are important for Max nuclear localization and for Max-mediated suppression of Myc transactivation. Mass spectrometry identification of modification sites, in vitro acetylation assay with p300, cellular acetylation assay with HDAC inhibitors and p300 overexpression, functional reporter assay, nuclear localization assay The Biochemical journal High 17217336
2008 In Drosophila, many biological activities of Myc do not require Max association: control of endoreplication and cell competition are Max-independent or only partially Max-dependent; a Myc mutant unable to interact with Max retains substantial biological activity; Myc controls RNA polymerase III transcription independently of Max. Drosophila genetics (Max loss-of-function and reduction-of-function mutations), Myc dimerization-mutant analysis, RNA Pol III transcription assay Nature genetics High 19165923
2011 Germline mutations in MAX (including loss-of-function mutations) cause hereditary pheochromocytoma; absence of MAX protein in tumors and loss of heterozygosity by uniparental disomy confirm MAX as a tumor suppressor; the rat pheochromocytoma cell line PC12 also lacks functional MAX. Exome sequencing, validation sequencing, immunohistochemistry for MAX protein, LOH analysis Nature genetics High 21685915
2014 Hypoxia in endothelial cells induces alternative splicing of MAX, producing two isoforms: isoform C (degraded by nonsense-mediated decay) and isoform E (encodes a highly unstable protein whose instability is conferred by 36 isoform-specific amino acids); both splicing events are unproductive and serve to downregulate wild-type MAX protein under hypoxia. RT-PCR isoform detection, protein stability assay, NMD inhibition, heterologous protein stability reporter FEBS letters Medium 25451222
2017 MAX is an epigenetic sensor of 5-carboxylcytosine (5caC): MAX exhibits greatest affinity for unmodified C or 5caC in the E-box CpG, and much reduced affinity for 5mC, 5hmC, or 5fC forms; crystal structure of MAX with 5caC-modified E-box revealed that Arg36 recognizes 5caC via a 5caC-Arg-Guanine triad; mutations of Arg35 or Arg36 abolish DNA binding while Arg60 mutation reduces binding but retains 5caC preference; MAX alterations in multiple myeloma cluster at Arg35, Arg36, and Arg60. Quantitative binding assays, X-ray crystallography of MAX–DNA complex, in vitro mutagenesis, analysis of >800 primary myeloma genomes Nucleic acids research High 27903915
2017 MAX inactivation (hemizygous or homozygous mutations) occurs in ~21% of GISTs and is an early event; loss of MAX protein expression is associated with p16 silencing (without p16 coding sequence deletion); re-introduction of MAX restores p16 expression and inhibits GIST proliferation. Next-generation sequencing, immunohistochemistry, MAX re-expression/rescue experiment in GIST cells with p16 and proliferation readouts Nature communications High 28270683
2019 B-cell-specific deletion of Max completely abrogates Eµ-Myc-driven lymphomagenesis while having only a modest effect on normal B-cell development; Max loss globally down-regulates Myc-activated genes in premalignant Eµ-Myc cells; Max loss leads to significant reduction in MYC protein levels and down-regulation of direct transcriptional targets including regulators of MYC stability; this MYC protein destabilization by Max loss is also observed in multiple cell lines treated with MYC-MAX dimerization inhibitors. B-cell-specific Cre-lox Max deletion, Eµ-Myc lymphoma model, RNA-seq, ChIP-seq, western blot for MYC protein levels Genes & development High 31395740
2022 The disordered MAX N-terminus interacts with the MYC:MAX DNA-binding domain (DBD) via electrostatic interactions, competitive with DNA binding; this intramolecular interaction accelerates DNA binding kinetics of MYC:MAX and MAX:MAX dimers while providing E-box specificity; Casein Kinase 2-mediated phosphorylation of two serines in the MAX N-terminus further enhances these effects. NMR spectroscopy (interaction mapping), Surface Plasmon Resonance (DNA binding kinetics), Casein Kinase 2 in vitro phosphorylation Journal of molecular biology High 36174765

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1993 Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell 747 8425219
1993 Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 690 8425218
1992 Myc and Max proteins possess distinct transcriptional activities. Nature 471 1406956
2003 X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 448 12553908
2011 Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nature genetics 415 21685915
1992 Myc and Max associate in vivo. Genes & development 414 1730411
1993 A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation. Genes & development 289 8224841
1992 Max: functional domains and interaction with c-Myc. Genes & development 281 1730412
2012 MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clinical cancer research : an official journal of the American Association for Cancer Research 259 22452945
1992 Casein kinase II inhibits the DNA-binding activity of Max homodimers but not Myc/Max heterodimers. Genes & development 234 1737614
2016 Biology of VO2 max: looking under the physiology lamp. Acta physiologica (Oxford, England) 229 27888580
2014 Soybean (Glycine max) expansin gene superfamily origins: segmental and tandem duplication events followed by divergent selection among subfamilies. BMC plant biology 197 24720629
2007 Improved low molecular weight Myc-Max inhibitors. Molecular cancer therapeutics 183 17876039
2015 Soybean (Glycine max) SWEET gene family: insights through comparative genomics, transcriptome profiling and whole genome re-sequence analysis. BMC genomics 170 26162601
2012 MAX and MYC: a heritable breakup. Cancer research 159 22706201
1996 Myc and Max homologs in Drosophila. Science (New York, N.Y.) 157 8929412
1992 Alternative forms of Max as enhancers or suppressors of Myc-ras cotransformation. Science (New York, N.Y.) 141 1566084
2006 The MAX-interacting transcription factor network. Seminars in cancer biology 125 16908182
1992 Myc and Max function as a nucleoprotein complex. Current opinion in genetics & development 119 1638116
1993 Regulation of human ornithine decarboxylase expression by the c-Myc.Max protein complex. The Journal of biological chemistry 112 8262968
2013 The use and misuse of V(c,max) in Earth System Models. Photosynthesis research 102 23564478
1992 Max and c-Myc/Max DNA-binding activities in cell extracts. Oncogene 102 1501888
1993 Distinct DNA binding preferences for the c-Myc/Max and Max/Max dimers. Nucleic acids research 98 8265351
2014 Comprehensive characterization and RNA-Seq profiling of the HD-Zip transcription factor family in soybean (Glycine max) during dehydration and salt stress. BMC genomics 97 25362847
2014 Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis. Biochimica et biophysica acta 95 24857747
1999 Mlx, a novel Max-like BHLHZip protein that interacts with the Max network of transcription factors. The Journal of biological chemistry 88 10593926
1999 Induction of max by adrenomedullin and calcitonin gene-related peptide antagonizes endothelial apoptosis. Molecular endocrinology (Baltimore, Md.) 87 10446908
2008 Max-independent functions of Myc in Drosophila melanogaster. Nature genetics 86 19165923
1993 Identification of casein kinase II phosphorylation sites in Max: effects on DNA-binding kinetics of Max homo- and Myc/Max heterodimers. Oncogene 86 8247525
2007 The glycine max xylem sap and apoplast proteome. Journal of proteome research 71 17696379
1993 Differential patterns of DNA binding by myc and max proteins. Proceedings of the National Academy of Sciences of the United States of America 70 8430110
2019 CRISPR-Cas9 mediated targeted disruption of FAD2-2 microsomal omega-6 desaturase in soybean (Glycine max.L). BMC biotechnology 69 30691438
2017 MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma. Nucleic acids research 69 27903915
2005 Mnt-Max to Myc-Max complex switching regulates cell cycle entry. The Journal of cell biology 68 15866886
1995 Carboxypeptidase M is identical to the MAX.1 antigen and its expression is associated with monocyte to macrophage differentiation. The Journal of biological chemistry 61 7797563
2016 Genome-wide analysis and expression profiling of glyoxalase gene families in soybean (Glycine max) indicate their development and abiotic stress specific response. BMC plant biology 59 27083416
2015 Genome-wide analysis and expression profiling of the PIN auxin transporter gene family in soybean (Glycine max). BMC genomics 58 26572792
1992 Expression, regulation, and chromosomal localization of the Max gene. Proceedings of the National Academy of Sciences of the United States of America 58 1557420
2020 Genome-wide identification and characterization of GRAS genes in soybean (Glycine max). BMC plant biology 57 32891114
2017 Soybean (Glycine max) WRINKLED1 transcription factor, GmWRI1a, positively regulates seed oil accumulation. Molecular genetics and genomics : MGG 56 29138932
1998 Regulation of GmNRT2 expression and nitrate transport activity in roots of soybean (Glycine max). Planta 56 9715532
1992 Opposite orientations of DNA bending by c-Myc and Max. Proceedings of the National Academy of Sciences of the United States of America 54 1323849
2011 Premetazoan ancestry of the Myc-Max network. Molecular biology and evolution 53 21571926
2020 Systematic analysis of 1298 RNA-Seq samples and construction of a comprehensive soybean (Glycine max) expression atlas. The Plant journal : for cell and molecular biology 51 32445587
1994 Differential binding of c-Myc and Max to nucleosomal DNA. Molecular and cellular biology 50 8196648
2019 Max deletion destabilizes MYC protein and abrogates Eµ-Myc lymphomagenesis. Genes & development 49 31395740
2017 MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nature communications 48 28270683
2013 Metabolic and Transcriptional Reprogramming in Developing Soybean (Glycine max) Embryos. Metabolites 48 24957996
2010 High level transgenic expression of soybean (Glycine max) GmERF and Gmubi gene promoters isolated by a novel promoter analysis pipeline. BMC plant biology 48 21050446
1997 Distinct roles for MAX protein isoforms in proliferation and apoptosis. The Journal of biological chemistry 48 9211884
2011 Small-molecule modulators of c-Myc/Max and Max/Max interactions. Current topics in microbiology and immunology 47 20680803
1995 The mycN/max protein complex in neuroblastoma. Short review. European journal of cancer (Oxford, England : 1990) 47 7576956
2023 Polystyrene micro and nanoplastics attenuated the bioavailability and toxic effects of Perfluorooctane sulfonate (PFOS) on soybean (Glycine max) sprouts. Journal of hazardous materials 45 36860033
2013 Coordination of nutrient availability and utilization by MAX- and MLX-centered transcription networks. Cold Spring Harbor perspectives in medicine 45 24003245
2011 Protein and metabolite composition of xylem sap from field-grown soybeans (Glycine max). Planta 45 21246215
2021 Dissecting the transcriptional regulation of proanthocyanidin and anthocyanin biosynthesis in soybean (Glycine max). Plant biotechnology journal 44 33539645
2015 Isolation and Characterization of a Novel Pathogenesis-Related Protein Gene (GmPRP) with Induced Expression in Soybean (Glycine max) during Infection with Phytophthora sojae. PloS one 41 26114301
2017 Strigolactones promote rhizobia interaction and increase nodulation in soybean (Glycine max). Microbial pathogenesis 34 29191709
2015 Distribution and evolution of the lectin family in soybean (Glycine max). Molecules (Basel, Switzerland) 34 25679048
2008 Hypocotyl-based Agrobacterium-mediated transformation of soybean (Glycine max) and application for RNA interference. Plant cell reports 34 18347801
2023 Physiological and transcriptome analysis of response of soybean (Glycine max) to cadmium stress under elevated CO2 concentration. Journal of hazardous materials 33 36860078
1997 Mnt: a novel Max-interacting protein and Myc antagonist. Current topics in microbiology and immunology 32 9308234
1992 Transcriptional activities of the Myc and Max proteins in mammalian cells. Current topics in microbiology and immunology 32 1490382
2017 GmMYB58 and GmMYB205 are seed-specific activators for isoflavonoid biosynthesis in Glycine max. Plant cell reports 31 28905215
2011 Evolution of the Max and Mlx networks in animals. Genome biology and evolution 31 21859806
2009 Myc's secret life without Max. Cell cycle (Georgetown, Tex.) 31 19887915
1993 Expression of the soybean (Glycine max) glutamate 1-semialdehyde aminotransferase gene in symbiotic root nodules. Plant physiology 31 8278535
2022 Time-series transcriptome comparison reveals the gene regulation network under salt stress in soybean (Glycine max) roots. BMC plant biology 30 35361109
2008 Enzyme-assisted aqueous extraction of oleosomes from soybeans (Glycine max). Journal of agricultural and food chemistry 29 18251501
2006 Lessons learned from Myc/Max/Mad knockout mice. Current topics in microbiology and immunology 29 16620030
2020 Progresses, Challenges, and Prospects of Genome Editing in Soybean (Glycine max). Frontiers in plant science 28 33193504
2006 Structural aspects of interactions within the Myc/Max/Mad network. Current topics in microbiology and immunology 28 16620027
2004 Determination of binding constant of transcription factor myc-max/max-max and E-box DNA: the effect of inhibitors on the binding. Biochimica et biophysica acta 26 14980448
2018 RNA sequencing analysis of salt tolerance in soybean (Glycine max). Genomics 25 29626511
2002 Soybean (Glycine max) cell wall composition and availability to feed enzymes. Journal of agricultural and food chemistry 25 11902936
1999 Analysis of the Max-binding protein MNT in human medulloblastomas. International journal of cancer 25 10446446
2022 Soil and foliar exposure of soybean (Glycine max) to Cu: Nanoparticle coating-dependent plant responses. NanoImpact 23 35588596
2022 The Disordered MAX N-terminus Modulates DNA Binding of the Transcription Factor MYC:MAX. Journal of molecular biology 23 36174765
2008 Nitrogen stress and the expression of asparagine synthetase in roots and nodules of soybean (Glycine max). Physiologia plantarum 23 18384503
2004 Expression and DNA-binding activity of MYCN/Max and Mnt/Max during induced differentiation of human neuroblastoma cells. Journal of cellular biochemistry 22 15258910
1997 Dimerization and DNA binding facilitate alpha-helix formation of Max in solution. Journal of biochemistry 22 9399572
2023 Functional characterization of Cinnamate 4-hydroxylase gene family in soybean (Glycine max). PloS one 21 37186600
2022 GmEIL4 enhances soybean (Glycine max) phosphorus efficiency by improving root system development. Plant, cell & environment 21 36419232
2008 Expression and purification of intact and functional soybean (Glycine max) seed ferritin complex in Escherichia coli. Journal of microbiology and biotechnology 21 18309275
2007 Max is acetylated by p300 at several nuclear localization residues. The Biochemical journal 21 17217336
2019 LncEGFL7OS regulates human angiogenesis by interacting with MAX at the EGFL7/miR-126 locus. eLife 20 30741632
2015 Functional analysis of duplicated Symbiosis Receptor Kinase (SymRK) genes during nodulation and mycorrhizal infection in soybean (Glycine max). Journal of plant physiology 19 25617765
2013 Changes in RNA Splicing in Developing Soybean (Glycine max) Embryos. Biology 19 24833227
2005 Structural and thermodynamical characterization of the complete p21 gene product of Max. Biochemistry 19 16171389
2018 Functional interplay between c-Myc and Max in B lymphocyte differentiation. EMBO reports 18 30126925
2021 Phospholipase D- and phosphatidic acid-mediated phospholipid metabolism and signaling modulate symbiotic interaction and nodulation in soybean (Glycine max). The Plant journal : for cell and molecular biology 17 33377234
2020 Analysis of Spatio-Temporal Transcriptome Profiles of Soybean (Glycine max) Tissues during Early Seed Development. International journal of molecular sciences 17 33066688
2018 Deciphering V̇O: limits of the genetic approach. The Journal of experimental biology 17 30381476
2014 Isolation and characterization of the brassinosteroid receptor gene (GmBRI1) from Glycine max. International journal of molecular sciences 17 24599079
2018 Genomic, molecular evolution, and expression analysis of NOX genes in soybean (Glycine max). Genomics 16 29621573
2019 Genome-wide identification and expression analysis of the VQ gene family in soybean (Glycine max). PeerJ 15 31497394
2018 PET-SUV Max and Upstaging of Lung Cancer. Heart, lung & circulation 15 29428202
2015 Ectopic phytocystatin expression increases nodule numbers and influences the responses of soybean (Glycine max) to nitrogen deficiency. Phytochemistry 15 25659749
2014 Hypoxia reduces MAX expression in endothelial cells by unproductive splicing. FEBS letters 15 25451222
2002 Unsaturated fatty acids bind Myc-Max transcription factor and inhibit Myc-Max-DNA complex formation. Cancer letters 15 12406560

Missed literature

Know a paper Affinage missed for MAX? Flag it for the maintainers and the community.

No submissions yet.